J Psychoactive Drugs. 2014 Jan-Mar;46(1):73-7. doi: 10.1080/02791072.2013.873843.
New Mexico was the first state to list post-traumatic stress disorder (PTSD) as a condition for the use of medical cannabis. There are no published studies, other than case reports, of the effects of cannabis on PTSD symptoms. The purpose of the study was to report and statistically analyze psychometric data on PTSD symptoms collected during 80 psychiatric evaluations of patients applying to the New Mexico Medical Cannabis Program from 2009 to 2011.
The Clinician Administered Posttraumatic Scale for DSM-IV (CAPS) was administered retrospectively and symptom scores were then collected and compared in a retrospective chart review of the first 80 patients evaluated.
Greater than 75% reduction in CAPS symptom scores were reported when patients were using cannabis compared to when they were not.
Cannabis is associated with reductions in PTSD symptoms in some patients, and prospective, placebo-controlled study is needed to determine efficacy of cannabis and its constituents in treating PTSD.
新墨西哥州是第一个将创伤后应激障碍（PTSD）列为使用医用大麻条件的州。除了病例报告外，目前尚无关于大麻对 PTSD 症状影响的公开研究。本研究的目的是报告和统计分析 2009 年至 2011 年间新墨西哥州医用大麻项目 80 名患者申请期间收集的 PTSD 症状的心理计量学数据。
采用 DSM-IV 创伤后量表（CAPS）进行回顾性评估，并对前 80 名接受评估的患者的首次回顾性图表审查中收集的症状评分进行比较。
与未使用大麻相比，当患者使用大麻时，CAPS 症状评分的减少大于 75%。
大麻与一些患者 PTSD 症状的减轻有关，需要进行前瞻性、安慰剂对照研究，以确定大麻及其成分治疗 PTSD 的疗效。
